Page 9 - Endpoints Related News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Endpoints related. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Endpoints Related Today - Breaking & Trending Today

Seres Therapeutics' ECOSPOR III Study Data on SER-109 Published in Journal of the American Medical Association

– Summarized data from the study s secondary endpoints show investigational oral microbiome therapeutic rapidly and durably lowered risk of recurrent C. difficile infection –
. | October 19, 2022 ....

United States , Centers For Disease , Exchange Commission , Seres Therapeutics Inc , Drug Administration , Journal Of The American Medical Association , Seres Therapeutics , American Medical Association , Disease Control , Chief Medical Officer , New England Journal , Microbiome Therapeutic , Recurrent Clostridioides , Randomized Clinical , Biologics License Application , Orphan Drug , Breakthrough Therapy , Infection Protection , Private Securities Litigation Reform Act , Quarterly Report , Nc Stock Exchange , Press Release , Nfection Mcrb Us81750r1023 ,

BioArctic: Lecanemab phase 3 Clarity AD study in early Alzheimer's disease meets primary and all key secondary endpoints with high statistical significance

STOCKHOLM, Sept. 28, 2022 /PRNewswire/ BioArctic AB's (publ) (Nasdaq Stockholm: BIOA B) partner Eisai today announced positive topline results for the large global Phase 3 confirmatory Clarity ....

Uppsala Lan , Oskar Bosson , Gunilla Osswald , Uppsala University , Vp Communications , National Institutes Of Health , National Institute On , Washington University School Of Medicine , Alzheimer Disease Cooperative Study , Alzheimer Network Trials Unit , Alzheimer Clinical Trial Consortium , Nasdaq Stockholm , Clinical Dementia Rating Sum , Clinical Trials , Confirm Safety , Participants With Early Alzheimer , From Baseline , Positron Emission Tomography , Disease Assessment Scale , Disease Composite Score , Disease Cooperative Study Activities , Daily Living Scale , Mild Cognitive Impairment , Clinical Trial Consortium , National Institute , National Institutes ,

Arcutis Announces Positive Topline Results from ARRECTOR Pivotal Phase 3 Trial of Roflumilast Foam 0.3% in Scalp and Body Psoriasis

Study met both co-primary endpoints and all secondary endpointsAt week eight, 67.3% of individuals treated with roflumilast foam achieved Scalp-Investigator Global Assessment Success compared to. | September 26, 2022 ....

United States , Eric Mcintyre , Amanda Sheldon , Exchange Commission , Head Of Corporate Communications , Globenewswire Inc , Arcutis Biotherapeutics Inc , Scalp Investigator Global Assessment , Body Investigator Global Assessment , Rial Employing , Arcutis Biotherapeutics , Nc Stock Exchange , Press Release , Ompared Arqt Us03969k1088 ,

In Akero Therapeutics' Phase 2b HARMONY Study, Both the 50mg and 28mg EFX Doses Achieved Statistical Significance on Primary and Secondary Histology Endpoints after 24 Weeks

50mg (41%) and 28mg (39%) groups demonstrated =1 stage improvement in fibrosis without worsening of NASH, double the placebo rate (20%) 50mg (76%) and 28mg (47%) groups demonstrated NASH resolution ....

United States , Sarah Oconnell , Andrew Cheng , Linkedinand Twitterfor , Stephen Harrison , Christina Tartaglia , Pa Fibroscan , Exchange Commission , Akero Therapeutics Inc , Pinnacle Clinical Research , Liver Fat , Key Markers , Change From Baseline , Fat Fraction , Key Cardio Metabolic , Conference Call , Private Securities Litigation Reform Act , Annual Report , Quarterly Report ,

Regeneron: Aflibercept 8 Mg Meets Primary Endpoints In Two Trials For DME And WAMD

WASHINGTON (dpa-AFX) - Regeneron Pharmaceuticals, Inc. (REGN) reported that the primary endpoints were met in two trials investigating aflibercept 8 mg with 12- and 16-week dosing regimens in patients ....

United States , Bayer Ag , Regeneron Pharmaceuticals Inc , More Such Health News ,